Table 3.
Analyses of risk factors for hepatocellular carcinoma recurrence after deceased donor liver transplantation.
| Factors | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |
| Post-reperfusion AST activity (continuous) | 1.17 (0.72–1.89) | 0.521 | ||
| Post-reperfusion AST activity (upper quartile) | 1.23 (0.52–2.91) | 0.638 | ||
| Post-reperfusion ALT activity (continuous) | 1.07 (0.67–1.72) | 0.773 | ||
| Post-reperfusion ALT activity (upper quartile) | 0.77 (0.29–2.04) | 0.602 | ||
| Post-reperfusion LDH activity (continuous) | 1.13 (0.73–1.76) | 0.575 | ||
| Post-reperfusion LDH activity (upper quartile) | 1.66 (0.73–3.78) | 0.226 | ||
| Peak postoperative bilirubin concentration (continuous) | 0.86 (0.51–1.47) | 0.592 | ||
| Peak postoperative bilirubin concentration (upper quartile) | 0.67 (0.25–1.78) | 0.424 | ||
| Peak postoperative INR (continuous) | 0.81 (0.41–1.60) | 0.553 | ||
| Peak postoperative INR (upper quartile) | 0.91 (0.34–2.42) | 0.854 | ||
| Post-reperfusion GGTP activity (continuous) | 1.20 (0.67–2.15) | 0.534 | ||
| Post-reperfusion GGTP activity (upper quartile) | 1.36 (0.59–3.12) | 0.474 | ||
| Total ischemic time | 1.02 (0.83–1.24) | 0.866 | ||
| Cold ischemic time | 1.07 (0.85–1.35) | 0.544 | ||
| Warm ischemic time | 1.00 (0.84–1.19) | 0.963 | ||
| Donor age | 1.00 (0.97–1.03) | 0.896 | ||
| Male donor sex | 0.52 (0.24–1.12) | 0.095 | ||
| Number of tumors | 1.25 (1.12–1.41) | <0.001 | 1.21 (1.06–1.39) | 0.004 |
| Diameter of the largest tumor | 1.02 (1.01–1.03) | 0.001 | ||
| Total tumor volume | 1.01 (1.00–1.03) | 0.170 | ||
| Alpha-fetoprotein concentration | 1.31 (1.15–1.50) | <0.001 | 1.29 (1.12–1.47) | <0.001 |
| Microvascular invasion | 4.28 (1.99–9.24) | <0.001 | 2.67 (1.22–5.84) | 0.014 |
| Poor tumor differentiation | 4.05 (1.71–9.59) | 0.002 | 3.35 (1.38–8.13) | 0.007 |
| Neoadjuvant treatment | 2.04 (0.91–4.54) | 0.082 | ||
| Male recipient sex | 0.64 (0.29–1.42) | 0.269 | ||
| Recipient age | 1.01 (0.96–1.05) | 0.809 | ||
| Hepatitis C virus infection | 0.89 (0.41–1.95) | 0.770 | ||
| Hepatitis B virus infection | 1.16 (0.54–2.47) | 0.703 | ||
| Model for End-stage Liver Disease | 0.93 (0.84–1.03) | 0.186 | ||
| Intraoperative PRBC transfusions | 0.99 (0.92–1.07) | 0.839 | ||
| Intraoperative FFP transfusions | 0.97 (0.89–1.05) | 0.470 | ||
Hazard ratios for continuous variables are given per: 1 loge (U/L) increase for AST, ALT, LDH, and GGTP activity; 1 increase for INR; 1 hour increase for total and cold ischemic times; 10 minute increase for warm ischemic time; 1 year increase for recipient and donor age; 1 increase for tumor number; 1 mm increase for diameter of the largest tumor; 10 cm3 increase for total tumor volume; 1 loge (ng/ml) increase for alpha-fetoprotein concentration; 1 point increase for Model for End-stage Liver Disease; and 1 unit increase for transfusions. HR - hazard ratio; 95% CI – 95% confidence interval; AST – aspartate transaminase; ALT – alanine transaminase; GGTP – gamma-glutamyl transpeptidase; INR – international normalized ratio; LDH – lactate dehydrogenase; PRBC – packed red blood cells; FFP – fresh frozen plasma